Neurocrine Biosciences
NBIX
#1490
Rank
HK$113.61 B
Marketcap
HK$1,118
Share price
0.84%
Change (1 day)
3.73%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): HK$55.06

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is HK$55.32. In 2025 the company made an earnings per share (EPS) of HK$37.82 an increase over its 2024 EPS that were of HK$26.52.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$55.0645.57%
2025HK$37.8242.6%
2024HK$26.5233.07%
2023HK$19.9357.76%
2022HK$12.6369.47%
2021HK$7.45-78.21%
2020HK$34.21990%
2019HK$3.1481.82%
2018HK$1.73-113.5%
2017-HK$12.790.62%
2016-HK$12.7157.28%
2015-HK$8.0825.61%
2014-HK$6.4318.84%
2013-HK$5.41-1085.71%
2012HK$0.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$5.96-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$28.02-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$234.50 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$5.89-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$15.93-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$37.90-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$59.25-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$14.72-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK